当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
Bivigam, Immune Globulin Intravenous (Human)
申请企业
ADMA Biologics, Inc.
药品名称
Bivigam, Immune Globulin Intravenous (Human)
承诺描述
Conduct a Phase IV, Multicentre, Open-Label Study to Evaluate the Efficacy and Safety of BIVIGAM in Primary Immune Deficiency Disorders in Children and Adolescents ages 2 to 16.